Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-034522
Filing Date
2020-07-30
Accepted
2020-07-30 08:08:56
Documents
51
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q odt-10q_20200630.htm   iXBRL 10-Q 1133524
2 EX-31.1 odt-ex311_6.htm EX-31.1 18260
3 EX-31.2 odt-ex312_7.htm EX-31.2 18342
4 EX-32.1 odt-ex321_8.htm EX-32.1 15072
5 GRAPHIC gt015yfy3ciw000001.jpg GRAPHIC 28085
  Complete submission text file 0001564590-20-034522.txt   3788655

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA odt-20200630.xsd EX-101.SCH 28722
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE odt-20200630_cal.xml EX-101.CAL 28989
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE odt-20200630_def.xml EX-101.DEF 54920
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE odt-20200630_lab.xml EX-101.LAB 232962
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE odt-20200630_pre.xml EX-101.PRE 162572
11 EXTRACTED XBRL INSTANCE DOCUMENT odt-10q_20200630_htm.xml XML 530728
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
Odonate Therapeutics, Inc. (Filer) CIK: 0001717452 (see all company filings)

EIN.: 822493065 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38318 | Film No.: 201059295
SIC: 2834 Pharmaceutical Preparations